{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:24:38Z","timestamp":1780068278960,"version":"3.54.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["PG14-008-TR2"],"award-info":[{"award-number":["PG14-008-TR2"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clon.2026.104124","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:50:23Z","timestamp":1773589823000},"page":"104124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Predicting High-Dose-Rate Brachytherapy Boost Benefit Using Hypoxia and Angiogenesis Gene Expression in Localised Prostate Cancer"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-0866","authenticated-orcid":false,"given":"T.","family":"Lodhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-3130","authenticated-orcid":false,"given":"C.G.","family":"Quiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-9567","authenticated-orcid":false,"given":"P.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clon.2026.104124_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on Prostate Cancer Epidemiology and Risk Factors\u2014A Systematic Review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clon.2026.104124_bib2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.clon.2026.104124_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.brachy.2025.06.005","article-title":"High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement","volume":"24","author":"Patel","year":"2025","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2026.104124_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13014-015-0366-z","article-title":"The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer","volume":"10","author":"Smolska-Ciszewska","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104124_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clon.2026.104124_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/diagnostics12030656","article-title":"Cell signaling pathways that promote radioresistance of cancer cells","volume":"12","author":"Ouellette","year":"2022","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.clon.2026.104124_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1677\/erc.1.00728","article-title":"Hypoxia-inducible factor-1 in human breast and prostate cancer","volume":"13","author":"Kimbro","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.clon.2026.104124_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2005.11.044","article-title":"An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance","volume":"65","author":"Carnell","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104124_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00924","article-title":"Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer","volume":"9","author":"Pang","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104124_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2014.604","article-title":"The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer","volume":"112","author":"Ragnum","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2026.104124_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2018.04.019","article-title":"Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer","volume":"31","author":"Yang","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clon.2026.104124_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2019.04.019","article-title":"Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb)","volume":"137","author":"Bhattacharya","year":"2019","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clon.2026.104124_bib13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2024.10.002","article-title":"Hypoxia-Associated Gene Signatures Are Not Prognostic in High-Risk Localized Prostate Cancers Undergoing Androgen Deprivation Therapy With Radiation Therapy","volume":"121","author":"Reardon","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"10.1016\/j.clon.2026.104124_bib14","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-07-0561","article-title":"Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response","volume":"67","author":"Milosevic","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clon.2026.104124_bib15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijrobp.2010.02.060","article-title":"Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI","volume":"80","author":"Alonzi","year":"2011","journal-title":"Int J Radiat Oncology\u2217 Biology\u2217 Phys"},{"issue":"4","key":"10.1016\/j.clon.2026.104124_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.clon.2026.104124_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clon.2026.104124_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0022-5347(01)62925-2","article-title":"CD34 IMMUNOHISTOCHEMICAL ASSESSMENT OF ANGIOGENESIS AS A PROGNOSTIC MARKER FOR PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY","volume":"160","author":"Bettencourt","year":"1998","journal-title":"The J Urol"},{"key":"10.1016\/j.clon.2026.104124_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2020.05.007","article-title":"GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers","volume":"485","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clon.2026.104124_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fcell.2019.00004","article-title":"Hypoxia-Modified Cancer Cell Metabolism","volume":"7","author":"Al","year":"2019","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.clon.2026.104124_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.urology.2009.08.024","article-title":"Expression and Localization of Hypoxia Proteins in Prostate Cancer: Prognostic Implications After Radical Prostatectomy","volume":"75","author":"Jans","year":"2010","journal-title":"Urology"},{"issue":"21","key":"10.1016\/j.clon.2026.104124_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215344","article-title":"Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clon.2026.104124_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s11658-020-00212-1","article-title":"Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia","volume":"25","author":"Bartoszewska","year":"2020","journal-title":"Cell Mol Biol Lett"},{"issue":"1035","key":"10.1016\/j.clon.2026.104124_bib24","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.clon.2026.104124_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","article-title":"HIF-1\u03b1 signaling: Essential roles in tumorigenesis and implications in targeted therapies","volume":"11","author":"Zhao","year":"2024","journal-title":"Genes Dis"},{"issue":"16","key":"10.1016\/j.clon.2026.104124_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/pros.24428","article-title":"Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy","volume":"82","author":"Filon","year":"2022","journal-title":"The Prostate"},{"key":"10.1016\/j.clon.2026.104124_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.redox.2018.03.017","article-title":"GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress","volume":"17","author":"Gonzalez-Menendez","year":"2018","journal-title":"Redox Biol"},{"issue":"2","key":"10.1016\/j.clon.2026.104124_bib28","first-page":"738","article-title":"Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity","volume":"5","author":"Ishiguro","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.clon.2026.104124_bib29","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.18632\/oncotarget.23225","article-title":"Hypoxia-inducible factor-1\u03b1 activates transforming growth factor-\u03b21\/Smad signaling and increases collagen deposition in dermal fibroblasts","volume":"9","author":"Mingyuan","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.clon.2026.104124_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s44324-025-00063-4","article-title":"ECM formation and degradation during fibrosis, repair, and regeneration","volume":"3","author":"Mayorca-Guiliani","year":"2025","journal-title":"Npj Metab Health Dis"},{"issue":"1","key":"10.1016\/j.clon.2026.104124_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12935-021-01897-w","article-title":"Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clon.2026.104124_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108610","article-title":"The therapeutic potential of targeting the CHD protein family in cancer","volume":"256","author":"Zhang","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.clon.2026.104124_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030499","article-title":"Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter","volume":"13","author":"Hompland","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clon.2026.104124_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061163","article-title":"The Role of \u03b1v\u03b23 Integrin in Cancer Therapy Resistance","volume":"12","author":"Pachane","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.clon.2026.104124_bib35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0360-3016(02)03007-9","article-title":"Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation","volume":"54","author":"Popple","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"947","key":"10.1016\/j.clon.2026.104124_bib36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1259\/bjr\/18700614","article-title":"Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data","volume":"79","author":"Wang","year":"2006","journal-title":"Br J Radiol"},{"issue":"28","key":"10.1016\/j.clon.2026.104124_bib37","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO-25-00274","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial","volume":"43","author":"Menne Guricov\u00e1","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104124_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104124_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104436","article-title":"Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation","volume":"88","author":"Wilkins","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.clon.2026.104124_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/238757","article-title":"Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer","volume":"2015","author":"Wilkins","year":"2015","journal-title":"Biomed Res Int"},{"issue":"16","key":"10.1016\/j.clon.2026.104124_bib41","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.3390\/ijms26167667","article-title":"Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment","volume":"26","author":"Lopez-Valcarcel","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.clon.2026.104124_bib42","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-17-0038","article-title":"A gene signature for selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer patients","volume":"23","author":"Yang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2026.104124_bib43","series-title":"Prostate radiotherapy with carbogen and nicotinamide. Final results of the phase 1b\/II PROCON trial","author":"Yip","year":"2020"},{"key":"10.1016\/j.clon.2026.104124_bib44","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/j.annonc.2020.08.2083","article-title":"689TiP NRG Oncology\u2019s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)","volume":"31","author":"Zumsteg","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104124_bib45","unstructured":"Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, et al. Genomic and transcriptomic profiling of Radiation resistant, Locally Recurrent Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics."}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:19:21Z","timestamp":1779448761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"alternative-id":["S0936655526000956"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104124","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting High-Dose-Rate Brachytherapy Boost Benefit Using Hypoxia and Angiogenesis Gene Expression in Localised Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"104124"}}